Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep;38(5):1406.
doi: 10.1111/pde.14809.

Commentary on "Hair and skin predict cardiomyopathies: Carvajal and erythrokeratodermia cardiomyopathy syndromes"

Alexandra M Ritter  1 , Harriet Bagnal Hinen  2 , Keith Adam Choate  3 , Lara Wine Lee  2
Affiliations
Comment

Commentary on "Hair and skin predict cardiomyopathies: Carvajal and erythrokeratodermia cardiomyopathy syndromes"

Alexandra M Ritter et al. Pediatr Dermatol. 2021 Sep.
No abstract available

Keywords: cardiocutaneous syndrome; erythrokeratodermia cardiomyopathy syndrome; genetics; ustekinumab.

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Sun Q, Wine Lee L, Hall EK, Choate KA, Elder RW. Hair and skin predict cardiomyopathies: carvajal and erythrokeratodermia cardiomyopathy syndromes. Pediatr Dermatol. 2021;38(1):31-38. 10.1111/pde.14478
    1. Cline A, Bartos GJ, Strowd LC, Feldman SR. Biologic treatment options for pediatric psoriasis and atopic dermatitis. Children. 2019;6(9):103. 10.3390/children6090103
    1. Paller AS, Czarnowicki T, Renert-Yuval Y, et al. The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: immunophenotyping and response to ustekinumab. J Am Acad Dermatol. 2018;78(3):498-505.e2. 10.1016/j.jaad.2017.10.026
    1. Chavannes M, Martinez-Vinson C, Hart L, et al. Management of paediatric patients with medically refractory crohn's disease using ustekinumab: a multi-centred cohort study. J Crohns Colitis. 2019;13(5):578-584. 10.1093/ecco-jcc/jjy206
    1. Rosh JR, Turner D, Griffiths A, et al. Ustekinumab in pediatric patients with moderately to severely active crohn's disease pharmacokinetics, safety, and efficacy results from unistar, a phase 1 study. [published online ahead of print, 2021 may 26]. J Crohns Colitis. 2021;jjab089. 10.1093/ecco-jcc/jjab089

LinkOut - more resources